Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsDeborah Doroshow, MD, PhD
Assistant Professor AdjunctAbout
Copy Link
Titles
Assistant Professor Adjunct
Academic Affiliate in the History of Medicine
Biography
Deborah Doroshow is Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Adjunct Assistant Professor of the History of Medicine at the Yale University School of Medicine.
She graduated from Harvard College in 2004 with a B.A. in History and Science, where she wrote a senior thesis entitled "The Injection of Insulin Into American Psychiatry," which explored the history of insulin coma therapy for schizophrenia. It was awarded the Thomas Temple Hoopes Award for outstanding senior thesis, and a portion of it was subsequently published in the Journal of the History of Medicine and Allied Sciences.
She earned her Ph.D. in History with distinction (concentration in the History of Science and Medicine) from Yale University in December 2012, winning the Edwin W. Small prize for outstanding dissertation in American History and the Pressman Career Development Award from the American Association of the History of Medicine. Her book, Emotionally Disturbed: A History of Caring for America's Troubled Children, was published by the University of Chicago Press in 2019.
Additional historical work has included a study of bedwetting alarms and parenting practices in mid-twentieth century America (Isis, 2010) and a history of laws mandating premarital syphilis testing (Social History of Medicine, 2019). She is an active member of the American Association for the History of Medicine and enjoys mentoring clinician-historians in training.
Deborah earned her M.D. from Harvard Medical School in 2013. She completed her internship and residency in internal medicine at the Yale University School of Medicine in 2015 and her fellowship in hematology and oncology, also at Yale, in 2019. At Mount Sinai, she treats adults with lung cancer as well as adults with a variety of solid tumors as part of the Early Phase Trials Unit, where her work focuses on the DNA damage response.
Appointments
History of Medicine
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Resident
- Yale University School of Medicine (2015)
- MD
- Harvard Medical School (2013)
- PhD
- Yale University, History (2012)
- AB
- Harvard College, History and Science (2004)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-2221-9818
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Elizabeth Horn Prsic, MD
Erin Hofstatter, MD
Joseph Paul Eder, MD
John L Vaughn, MD, MS
Michael Cecchini, MD
Nelson LaMarche, PhD
History of Medicine
Lung Neoplasms
Publications
2025
Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar Awards
Barr J, Doroshow D, Olszewski T, Ehrenberger K. Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar Awards. Journal Of The History Of Medicine And Allied Sciences 2025, 81: 111-120. PMID: 41251538, DOI: 10.1093/jhmas/jraf018.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsReal-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy
Nieva J, Wang X, Doroshow D, Servidio L, Cooper M, Lau Y, Karia P, Robichaux J. Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy. Oncology And Therapy 2025, 1-16. PMID: 41206837, DOI: 10.1007/s40487-025-00395-7.Peer-Reviewed Original ResearchAltmetricConceptsEpidermal growth factor receptor geneNon-small cell lung cancerAdvanced non-small cell lung cancerAtypical EGFR mutationsEpidermal growth factor receptor gene mutationsFirst-line osimertinibEGFR mutationsCell lung cancerOverall survivalTreatment patternsStage IIIB-IV non-small cell lung cancerLung cancerFollow-upGroup ADe novo T790MGrowth factor receptor geneCompound EGFR mutationsProgression-free survivalMedian Follow-UpFirst-line treatmentOsimertinib combinationOsimertinib monotherapyMethodsMedical recordsMutation subgroupsT790M1308 Disease-free survival with neoadjuvant cemiplimab +/- stereotactic body radiation in resectable hepatocellular carcinoma
Feng D, Crowley F, Hapanowicz O, Venturini N, Lucas N, Wu K, Wilk J, Cuevas J, Fitzgerald L, Fazilov G, Myint Z, Sadek N, Chin T, Noel C, Devraj V, Fu W, Ahn S, Hamon P, Hennequin C, Fiel M, Ward S, Brody R, Taouli B, Bane O, Kim E, Garcia-Reyes K, Buckstein M, Gunasekaran G, Tabrizian P, Doroshow D, Zhao Q, Sun D, Kaul M, Brennan L, Thanigaimani P, Miller E, Uldrick T, Lowy I, Schwartz M, Merad M, Marron T. 1308 Disease-free survival with neoadjuvant cemiplimab +/- stereotactic body radiation in resectable hepatocellular carcinoma. 2025, a1543-a1543. DOI: 10.1136/jitc-2025-sitc2025.1308.Peer-Reviewed Original ResearchP3.12.39 Long-Term Overall Survival in Advanced EGFRm NSCLC Treated With 1L Osimertinib: Results From the US, Japan, Germany and China
Nieva J, Karia P, Chander P, Cooper M, Doroshow D, Tech S, Eberhardt W, Griesinger F, Muto M. P3.12.39 Long-Term Overall Survival in Advanced EGFRm NSCLC Treated With 1L Osimertinib: Results From the US, Japan, Germany and China. Journal Of Thoracic Oncology 2025, 20: s482-s483. DOI: 10.1016/j.jtho.2025.09.901.Peer-Reviewed Original ResearchConceptsDocumentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials
Karol A, Paredes R, Argulian A, Joshi H, Weintraub L, Oguntuyo K, Miller J, Fujiwara Y, Doroshow D, Galsky M. Documentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials. Cancer 2025, 131: e70106. PMID: 41004397, DOI: 10.1002/cncr.70106.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsClinical trialsCancer clinical trialsPatient withdrawalRetention strategiesMedian proportionWithdrawal of patientsProportion of patientsCross-sectional studyProportion of withdrawalsTreatment toxicityPrimary outcomeAnticancer therapySecondary outcomesTrial qualityPatientsEfficacy estimatesPatient-initiatedTrial protocolTrialsWithdrawalDocumentation practicesStudy validityCancerTrial integrityPrevalenceEvaluating palliative care needs of early-phase clinical trial patients.
Crowley F, Zeng L, Hobensack M, Lehrman S, Afezolli D, Kelly L, Wey W, Chen J, Austin V, Easton E, Pagala A, Wu K, Lucas N, Wilk J, Marron T, Smith C, Gelfman L, Doroshow D. Evaluating palliative care needs of early-phase clinical trial patients. Journal Of Clinical Oncology 2025, 43: 12086-12086. DOI: 10.1200/jco.2025.43.16_suppl.12086.Peer-Reviewed Original ResearchConceptsPalliative careEnd-of-lifeEarly phase clinical trialsOutpatient PCReferral systemPalliative care needsSpecialty palliative careCancer type distributionPC servicesCare needsRetrospective cohort studyEvaluate demographic characteristicsPrevalent symptomsRate of constipationPC guidelinesPhysical discomfortCohort studyIncrease accessFisher's exact testPhase clinical trialsClinical trial patientsDemographic characteristicsMann-Whitney U testChi-squareCategorical variablesNeoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Feng D, Crowley F, Hapanowicz O, Venturini N, Lucas N, Wu K, Wilk J, Sadek N, Hamon P, Hennequin C, Devraj V, Thanigaimani P, Uldrick T, Miller E, Lowy I, Doroshow D, Tabrizian P, Schwartz M, Merad M, Marron T. Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16320.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsRelapse-free survivalOverall response rateAnti-PD-1Single-institution experienceResectable hepatocellular carcinomaNeoadjuvant immunotherapyHepatocellular carcinomaAdverse eventsTumor necrosisPathological responseSingle-agent anti-PD-1Early-stage hepatocellular carcinomaEarly-phase clinical trialsGrade 3 hepatitisAdvanced hepatocellular carcinomaDelay of surgerySurvival of patientsCombination immunotherapyNeoadjuvant settingAdjuvant immunotherapyResected tumorMetastatic diseaseImmunotherapy regimensNeoadjuvant nivolumabAssessing patient withdrawal in cancer clinical trials: A systematic evaluation of reasons and transparency in reporting.
Argulian A, Karol A, Paredes R, Oguntuyo K, Weintraub L, Miller J, Fujiwara Y, Joshi H, Doroshow D, Galsky M. Assessing patient withdrawal in cancer clinical trials: A systematic evaluation of reasons and transparency in reporting. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23003.Peer-Reviewed Original ResearchCitationsConceptsCancer clinical trialsOncology clinical trialsPhase III oncology clinical trialsSupportive care trialsPatient withdrawalClinical trialsLack of standard practicesPrimary cancer typeCare trialsFollow-upPatient-initiatedHigh attrition ratesPatients' intentionStandard careCONSORT diagramControl armDocumented reasonsOncology trialsAttrition ratesMedian Follow-UpTrial integrityWithdrawal reasonsConsent documentsTrial designSelection biasThe landscape and effectiveness of patient retention strategies in cancer clinical trials.
Weintraub L, Karol A, Paredes R, Argulian A, Oguntuyo K, Miller J, Fujiwara Y, Joshi H, Doroshow D, Galsky M. The landscape and effectiveness of patient retention strategies in cancer clinical trials. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23005.Peer-Reviewed Original ResearchConceptsTherapeutic cancer clinical trialsCancer clinical trialsRetention strategiesRate ratiosSupportive care trialsConfidence intervalsPatient education materialsEfficacy of current practicesBenefits of participationRandomized Controlled TrialsCare trialsClinical trialsPatient retentionReduced generalizabilityContact patientsUnivariate linear regressionInclusion criteriaPersonalized interventionsEducational materialsControlled TrialsIncreased likelihoodMulti-siteProtocol documentsSupportive careCurrent practicesFactors influencing withdrawal without a defined reason in oncology trials.
Paredes R, Karol A, Argulian A, Oguntuyo K, Weintraub L, Miller J, Fujiwara Y, Joshi H, Doroshow D, Galsky M. Factors influencing withdrawal without a defined reason in oncology trials. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23014.Peer-Reviewed Original ResearchConceptsRate ratiosImprove participant retentionSupportive care trialsPatient-level factorsCombination therapyParticipant flow diagramEnrollment sizeCare trialsSolid tumorsInterpretation of clinical trial resultsParticipant retentionIndustry-sponsored trialsPatient interactionsAssociated with significantly higher ratesInclusion criteriaMedian Follow-UpTrial enrollmentIncreased likelihoodSignificantly higher ratesMultivariate regressionClinical trial resultsMulti-siteTrial designPatient enrollmentDefinitive RT
Get In Touch
Copy Link